Abstract: Autism spectrum disorder (ASD) is a range of neurodevelopmental diseases characterized by social dysfunction and stereotypic behaviors. The etiology of ASD remains largely unexplored, resulting in a diverse array of described clinical manifestations and varying degrees of severity. Currently, there are no drugs approved by a supervisory organization that can effectively treat the core symptoms of ASD. Childhood and adolescence are crucial stages for making significant achievements in ASD treatment, necessitating the development of drugs specifically for these periods. Based on the drug targets and mechanisms of action, it can be found that atypical psychotropic medications, anti-inflammatory and antioxidant medications, hormonal medications, ion channel medications, and gastrointestinal medications have shown significant improvement in treating the core symptoms of ASD in both children and adolescents. In addition, comparisons of drugs within the same category regarding efficacy and safety have been made to identify better alternatives and promote drug development. While further evaluation of the effectiveness and safety of these medications is needed, they hold great potential for widespread application in the clinical treatment of the principal symptoms of ASD.

自闭症谱系障碍核心症状的药物疗法

[1]AlsayoufHA, TaloH, BiddappaML, et al., 2021. Risperidone or aripiprazole can resolve autism core signs and symptoms in young children: case study. Children (Basel), 8(5):318.

[2]AlsayoufHA, TaloH, BiddappaML, 2022. Core signs and symptoms in children with autism spectrum disorder improved after starting risperidone and aripiprazole in combination with standard supportive therapies: a large, single-center, retrospective case series. Brain Sci, 12(5):618.

[3]AnagnostouE, 2018. Clinical trials in autism spectrum disorder: evidence, challenges and future directions. Curr Opin Neurol, 31(2):119-125.

[4]ArabK, RossaryA, FlouriéF, et al., 2006. Docosahexaenoic acid enhances the antioxidant response of human fibroblasts by upregulating γ-glutamyl-cysteinyl ligase and glutathione reductase. Br J Nutr, 95(1):18-26.

[5]AranA, CassutoH, LubotzkyA, et al., 2019a. Brief report: cannabidiol-rich cannabis in children with autism spectrum disorder and severe behavioral problems—a retrospective feasibility study. J Autism Dev Disord, 49(3):1284-1288.

[6]AranA, EylonM, HarelM, et al., 2019b. Lower circulating endocannabinoid levels in children with autism spectrum disorder. Mol Autism, 10:2.

[7]AshwoodP, KrakowiakP, Hertz-PicciottoI, et al., 2011. Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome. Brain Behav Immun, 25(1):40-45.

[8]Bar-Lev SchleiderL, MechoulamR, SabanN, et al., 2019. Real life experience of medical cannabis treatment in autism: analysis of safety and efficacy. Sci Rep, 9:200.

[9]BatebiN, MoghaddamHS, HasanzadehA, et al., 2021. Folinic acid as adjunctive therapy in treatment of inappropriate speech in children with autism: a double-blind and placebo-controlled randomized trial. Child Psychiatry Hum Dev, 52(5):928-938.

[10]BentS, LawtonB, WarrenT, et al., 2018. Identification of urinary metabolites that correlate with clinical improvements in children with autism treated with sulforaphane from broccoli. Mol Autism, 9:35.

[11]BethlehemRAI, LombardoMV, LaiMC, et al., 2017. Intranasal oxytocin enhances intrinsic corticostriatal functional connectivity in women. Transl Psychiatry, 7(4):e1099.

[12]BritoAR, VairoGDPT, DiasAPBH, et al., 2021. Effect of prednisolone on language function in children with autistic spectrum disorder: a randomized clinical trial. J Pediatr (Rio J), 97(1):22-29.

[13]CaiQZ, FengL, YapKZ, 2018. Systematic review and meta-analysis of reported adverse events of long-term intranasal oxytocin treatment for autism spectrum disorder. Psychiatry Clin Neurosci, 72(3):140-151.

[14]CicalaG, BarbieriMA, SantoroV, et al., 2020. Safety and tolerability of antipsychotic drugs in pediatric patients: data from a 1-year naturalistic study. Front Psychiatry, 11:152.

[15]DantzerR, O'ConnorJC, FreundGG, et al., 2008. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci, 9(1):46-56.

[16]DebSS, RetzerA, RoyM, et al., 2020. The effectiveness of parent training for children with autism spectrum disorder: a systematic review and meta-analyses. BMC Psychiatry, 20:583.

[17]DoaeiS, BourbourF, TeymooriZ, et al., 2021. The effect of omega-3 fatty acids supplementation on social and behavioral disorders of children with autism: a randomized clinical trial. Pediatr Endocrinol Diabetes Metab, 27(1):12-18.

[18]DuffyFH, ShankardassA, McAnultyGB, et al., 2014. Corticosteroid therapy in regressive autism: a retrospective study of effects on the Frequency Modulated Auditory Evoked Response (FMAER), language, and behavior. BMC Neurol, 14:70.

[19]EckerC, BookheimerSY, MurphyDGM, 2015. Neuroimaging in autism spectrum disorder: brain structure and function across the lifespan. Lancet Neurol, 14(11):1121-1134.

[20]Fleury-TeixeiraP, CaixetaFV, Ramires da SilvaLC, et al., 2019. Effects of CBD-enriched Cannabis sativa extract on autism spectrum disorder symptoms: an observational study of 18 participants undergoing compassionate use. Front Neurol, 10:1145.

[21]FryeRE, JamesSJ, 2014. Metabolic pathology of autism in relation to redox metabolism. Biomark Med, 8(3):321-330.

[22]FryeRE, SlatteryJ, DelheyL, et al., 2018. Folinic acid improves verbal communication in children with autism and language impairment: a randomized double-blind placebo-controlled trial. Mol Psychiatry, 23(2):247-256.

[23]HacohenM, StolarOE, BerkovitchM, et al., 2022. Children and adolescents with ASD treated with CBD-rich cannabis exhibit significant improvements particularly in social symptoms: an open label study. Transl Psychiatry, 12:375.

[24]HadjikhaniN, ZürcherNR, RogierO, et al., 2015. Improving emotional face perception in autism with diuretic bumetanide: a proof-of-concept behavioral and functional brain imaging pilot study. Autism, 19(2):149-157.

[25]HerscuP, HandenBL, ArnoldLE, et al., 2020. The SOFIA study: negative multi-center study of low dose fluoxetine on repetitive behaviors in children and adolescents with autistic disorder. J Autism Dev Disord, 50(9):3233-3244.

[26]HetrickSE, McKenzieJE, BaileyAP, et al., 2021. New generation antidepressants for depression in children and adolescents: a network meta-analysis. Cochrane Database Syst Rev, 5(5):CD013674.

[27]HirotaT, KingBH, 2023. Autism spectrum disorder: a review. JAMA, 329(2):157-168.

[28]HuangHL, KuoCS, ChangTY, et al., 2021. An oral absorbent, AST-120, restores vascular growth and blood flow in ischemic muscles in diabetic mice via modulation of macrophage transition. J Mol Cell Cardiol, 155:99-110.

[29]JamesSJ, MelnykS, JerniganS, et al., 2006. Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism. Am J Med Genet B Neuropsychiatr Genet, 141B(8):947-956.

[30]KodakT, BergmannS, 2020. Autism spectrum disorder: characteristics, associated behaviors, and early intervention. Pediatr Clin North Am, 67(3):525-535.

[31]KompellaS, VittoriA, KroinJ, et al., 2022. Impact of antipsychotic use on readmission rates in children and adolescents with autism spectrum disorder and irritability. Cureus, 14(2):e22361.

[32]LeJ, ZhangL, ZhaoWH, et al., 2022. Infrequent intranasal oxytocin followed by positive social interaction improves symptoms in autistic children: a pilot randomized clinical trial. Psychother Psychosom, 91(5):335-347.

[33]LeeSH, RipkeS, NealeBM, et al., 2013. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet, 45(9):984-994.

[34]LeeTM, LeeKM, LeeCY, et al., 2021. Effectiveness of N-acetylcysteine in autism spectrum disorders: a meta-analysis of randomized controlled trials. Aust N Z J Psychiatry, 55(2):196-206.

[35]LemonnierE, DegrezC, PhelepM, et al., 2012. A randomised controlled trial of bumetanide in the treatment of autism in children. Transl Psychiatry, 2(12):e202.

[36]LemonnierE, VilleneuveN, SonieS, et al., 2017. Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders. Transl Psychiatry, 7(3):e1056.

[37]LordC, ElsabbaghM, BairdG, et al., 2018. Autism spectrum disorder. Lancet, 392(10146):508-520.

[38]LozovayaN, NardouR, TyzioR, et al., 2019. Early alterations in a mouse model of Rett syndrome: the GABA developmental shift is abolished at birth. Sci Rep, 9:9276.

[39]LuchtmanDW, SongC, 2013. Cognitive enhancement by omega-3 fatty acids from child-hood to old age: findings from animal and clinical studies. Neuropharmacology, 64:550-565.

[40]MalekM, Ashraf-GanjoueiA, MoradiK, et al., 2020. Prednisolone as adjunctive treatment to risperidone in children with regressive type of autism spectrum disorder: a randomized, placebo-controlled trial. Clin Neuropharmacol, 43(2):39-45.

[41]Martínez-GonzálezAE, Andreo-MartínezP, 2019. The role of gut microbiota in gastrointestinal symptoms of children with ASD. Medicina (Kaunas), 55(8):408.

[42]MechoulamR, ParkerLA, 2013. The endocannabinoid system and the brain. Annu Rev Psychol, 64(1):21-47.

[43]MomtazmaneshS, Amirimoghaddam-YazdiZ, MoghaddamHS, et al., 2020. Sulforaphane as an adjunctive treatment for irritability in children with autism spectrum disorder: a randomized, double-blind, placebo-controlled clinical trial. Psychiatry Clin Neurosci, 74(7):398-405.

[44]NiwaT, EmotoY, MaedaK, et al., 1991. Oral sorbent suppresses accumulation of albumin-bound indoxyl sulphate in serum of haemodialysis patients. Nephrol Dial Transplant, 6(2):105-109.

[45]PandinaGJ, BossieCA, YoussefE, et al., 2007. Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. J Autism Dev Disord, 37(2):367-373.

[46]PanekM, KawalecP, PilcA, et al., 2020. Developments in the discovery and design of intranasal antidepressants. Expert Opin Drug Discov, 15(10):1145-1164.

[47]ParelladaM, LlorenteC, CalvoR, et al., 2017. Randomized trial of omega-3 for autism spectrum disorders: effect on cell membrane composition and behavior. Eur Neuropsychopharmacol, 27(12):1319-1330.

[48]ParkerKJ, OztanO, LiboveRA, et al., 2017. Intranasal oxytocin treatment for social deficits and biomarkers of response in children with autism. Proc Natl Acad Sci USA, 114(30):8119-8124.

[49]PedrazziJFC, FerreiraFR, Silva-AmaralD, et al., 2022. Cannabidiol for the treatment of autism spectrum disorder: hope or hype?Psychopharmacology (Berl), 239(9):2713-2734.

[50]PintoriN, CariaF, deLuca MA, et al., 2023. THC and CBD: villain versus hero? Insights into adolescent exposure. Int J Mol Sci, 24(6):5251.

[51]ReddihoughDS, MarraffaC, MoutiA, et al., 2019. Effect of fluoxetine on obsessive-compulsive behaviors in children and adolescents with autism spectrum disorders: a randomized clinical trial. JAMA, 322(16):1561-1569.

[52]RenardE, LeheupB, Guéant-RodriguezRM, et al., 2020. Folinic acid improves the score of autism in the EFFET placebo-controlled randomized trial. Biochimie, 173:57-61.

[53]RossignolDA, FryeRE, 2012. Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis. Mol Psychiatry, 17(3):290-314.

[54]RylaarsdamL, Guemez-GamboaA, 2019. Genetic causes and modifiers of autism spectrum disorder. Front Cell Neurosci, 13:385.

[55]ScalaM, BiondiL, SerrettiA, et al., 2023. Obsessive-compulsive, psychotic, and autism dimensions overlap in real world: a case report. Clin Neuropharmacol, 46(4):149-152.

[56]SiafisS, ÇırayO, WuH, et al., 2022. Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis. Mol Autism, 13:10.

[57]Siegel-RamsayJE, RomaniukL, WhalleyHC, et al., 2021. Glutamate and functional connectivity ‒ support for the excitatory-inhibitory imbalance hypothesis in autism spectrum disorders. Psychiatry Res Neuroimaging, 313:111302.

[58]SikichL, KolevzonA, KingBH, et al., 2021. Intranasal oxytocin in children and adolescents with autism spectrum disorder. N Engl J Med, 385(16):1462-1473.

[59]SinghiP, MalhiP, 2023. Early diagnosis of autism spectrum disorder: what the pediatricians should know. Indian J Pediatr, 90(4):364-368.

[60]SprengersJJ, van AndelDM, ZuithoffNPA, et al., 2021. Bumetanide for core symptoms of autism spectrum disorder (BAMBI): a single center, double-blinded, participant-randomized, placebo-controlled, phase-2 superiority trial. J Am Acad Child Adolesc Psychiatry, 60(7):865-876.

[61]SrikanthaP, MohajeriMH, 2019. The possible role of the microbiota-gut-brain-axis in autism spectrum disorder. Int J Mol Sci, 20(9):2115.

[62]Stewart CampbellA, NeedhamBD, MeyerCR, et al., 2022. Safety and target engagement of an oral small-molecule sequestrant in adolescents with autism spectrum disorder: an open-label phase 1b/2a trial. Nat Med, 28(3):528-534.

[63]SurénP, RothC, BresnahanM, et al., 2013. Association between maternal use of folic acid supplements and risk of autism spectrum disorders in children. JAMA, 309(6):570-577.

[64]ThomRP, PereiraJA, SipsockD, et al., 2021. Recent updates in psychopharmacology for the core and associated symptoms of autism spectrum disorder. Curr Psychiatry Rep, 23(12):79.

[65]TyeC, RuniclesAK, WhitehouseAJO, et al., 2019. Characterizing the interplay between autism spectrum disorder and comorbid medical conditions: an integrative review. Front Psychiatry, 9:751.

[66]VahabzadehA, McDougleCJ, 2013. Maternal folic acid supplementation and risk of autism. JAMA, 309(21):2208.

[67]ValléeA, LecarpentierY, ValléeJN, 2021. Cannabidiol and the canonical WNT/β-catenin pathway in glaucoma. Int J Mol Sci, 22(7):3798.

[68]WangMY, LiuHY, MaZG, 2022. Roles of the cannabinoid system in the basal ganglia in Parkinson’s disease. Front Cell Neurosci, 16:832854.

[69]WeiD, LeeD, CoxCD, et al., 2015. Endocannabinoid signaling mediates oxytocin-driven social reward. Proc Natl Acad Sci USA, 112(45):14084-14089.

[70]WhitingPF, WolffRF, DeshpandeS, et al., 2015. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA, 313(24):2456-2473.

[71]WuJX, QinGY, 2023. The efficacy and safety of fluoxetine versus placebo for stroke recovery: a meta-analysis of randomized controlled trials. Int J Clin Pharm, 45(4):839-846.

[72]YangXL, LiangS, ZouMY, et al., 2018. Are gastrointestinal and sleep problems associated with behavioral symptoms of autism spectrum disorder?Psychiatry Res, 259:229-235.

[73]ŻebrowskaP, ŁaczmańskaI, ŁaczmańskiŁ, 2021. Future directions in reducing gastrointestinal disorders in children with ASD using fecal microbiota transplantation. Front Cell Infect Microbiol, 11:630052.

[74]ZhangLL, HuangCC, DaiY, et al., 2020. Symptom improvement in children with autism spectrum disorder following bumetanide administration is associated with decreased GABA/glutamate ratios. Transl Psychiatry, 10:9.

[75]ZimmermanAW, SinghK, ConnorsSL, et al., 2021. Randomized controlled trial of sulforaphane and metabolite discovery in children with autism spectrum disorder. Mol Autism, 12:38.